(Q38699406)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26775794%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

1 reference

14 July 2021

Plasma therapy against infectious pathogens, as of yesterday, today and tomorrow (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26775794%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

1 reference

14 July 2021

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26775794%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

author name string

O Garraud

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26775794%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

F Heshmati

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26775794%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

F Lefrere

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26775794%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

R Girot

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26775794%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

A Saillol

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26775794%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

S Laperche

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26775794%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

publication date

6 January 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26775794%20AND%20SRC:MED&resulttype=core&format=json

Transfusion Clinique et Biologique

5 March 2020

1 February 2016

1 reference

14 July 2021

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26775794%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

14 July 2021

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26775794%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26775794%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

page(s)

39-44

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26775794%20AND%20SRC:MED&resulttype=core&format=json

Immunotherapy throughout the decades: from Noon to now.

5 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2015.12.003

Immunotherapy in clinical medicine: historical perspective and current status

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2015.12.003

Mechanisms of immunotherapy: a historical perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2015.12.003

History of passive antibody administration for prevention and treatment of infectious diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2015.12.003

Immunotherapies in infectious diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2015.12.003

Polyclonal immunoglobulins and hyperimmune globulins in prevention and management of infectious diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2015.12.003

The use of antibodies in the prophylaxis and treatment of infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2015.12.003

Immunotherapy: the next 100 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2015.12.003

[Human rabies in France in 2004: update and management]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2015.12.003

Prophylaxis and therapy for Chikungunya virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2015.12.003

Successful passive and active immunization of cynomolgus monkeys against hepatitis E

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2015.12.003

Passive protection of mice against infection with Trypanosoma cruzi with plasma: the use of blood- and vector bug-derived trypomastigote challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2015.12.003

Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2015.12.003

Convalescent whole blood, plasma and serum in the prophylaxis of measles: JAMA, 12 April, 1926; 1180-1187.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2015.12.003

The use of Lassa fever convalescent plasma in Nigeria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2015.12.003

Lassa fever. Effective therapy with ribavirin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2015.12.003

Endemic Lassa fever in Liberia. IV. Selection of optimally effective plasma for treatment by passive immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2015.12.003

Progress in the experimental therapy of severe arenaviral infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2015.12.003

Prophylaxis of Rift Valley fever with antiviral drugs, immune serum, an interferon inducer, and a macrophage activator

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2015.12.003

Crimean-Congo Hemorrhagic Fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2015.12.003

Quantitation of passively acquired human immunodeficiency virus (HIV) antibodies in AIDS patients transfused with a plasma that is rich in HIV antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2015.12.003

Virological and immunological data of AIDS patients treated by passive immunotherapy (transfusions of plasma rich in HIV-1 antibodies).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2015.12.003

Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2015.12.003

Purification of severe acute respiratory syndrome hyperimmune globulins for intravenous injection from convalescent plasma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2015.12.003

Use of convalescent plasma therapy in SARS patients in Hong Kong

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2015.12.003

Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2015.12.003

The management of coronavirus infections with particular reference to SARS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2015.12.003

SARS: systematic review of treatment effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2015.12.003

The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2015.12.003

Treatment with convalescent plasma for influenza A (H5N1) infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2015.12.003

Adjunctive therapies and immunomodulatory agents in the management of severe influenza

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2015.12.003

Hark back: passive immunotherapy for influenza and other serious infections.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2015.12.003

A study in scarlet-convalescent plasma for severe influenza*.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2015.12.003

Hyperimmune intravenous immunoglobulin containing high titers of pandemic H1N1 hemagglutinin and neuraminidase antibodies provides dose-dependent protection against lethal virus challenge in SCID mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2015.12.003

Clinical research during a public health emergency: a systematic review of severe pandemic influenza management.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2015.12.003

Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2015.12.003

Practical limitations of convalescent plasma collection: a case scenario in pandemic preparation for influenza A (H1N1) infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2015.12.003

Preparation of commercial quantities of a hyperimmune human intravenous immunoglobulin preparation against an emerging infectious disease: the example of pandemic H1N1 influenza

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2015.12.003

Strategies for screening blood donors to source convalescent H1N1v plasma for intervention therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2015.12.003

The epidemiological and public health research response to 2009 pandemic influenza A(H1N1): experiences from Hong Kong

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2015.12.003

Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2015.12.003

Passive transfer of antibodies protects immunocompetent and imunodeficient mice against lethal Ebola virus infection without complete inhibition of viral replication.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2015.12.003

Evaluating large-scale blood transfusion therapy for the current Ebola epidemic in Liberia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2015.12.003

Using convalescent whole blood or plasma as passive immune therapy for the global war against Ebola

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2015.12.003

World Apheresis Association letter to the WHO: the World Apheresis Association urges the development of preparedness plans to make specific plasma available when urgently needed

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2015.12.003

Ebola virus convalescent blood products: where we are now and where we may need to go.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2015.12.003

Ebola: a call for blood transfusion strategy in sub-Saharan Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2015.12.003

The Use of TKM-100802 and Convalescent Plasma in 2 Patients With Ebola Virus Disease in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2015.12.003

Therapeutic antibodies in HIV treatment--classical approaches to novel advances

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2015.12.003

Protection against dengue disease by synthetic nucleic acid antibody prophylaxis/immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2015.12.003

Dengue pathogenesis: a disease driven by the host response.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2015.12.003

Who should donate blood? Policy decisions on donor deferral criteria should protect recipients and be fair to donors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2015.12.003

Passive antibody therapy of Lassa fever in cynomolgus monkeys: importance of neutralizing antibody and Lassa virus strain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2015.12.003

7 January 2021

inferred from DOI database lookup

Large-scale convalescent blood and plasma transfusion therapy for Ebola virus disease

1 reference

12 December 2020

The Use of Ebola Convalescent Plasma to Treat Ebola Virus Disease in Resource-Constrained Settings: A Perspective From the Field

1 reference

12 December 2020

Successful treatment of avian influenza with convalescent plasma

1 reference

12 December 2020

Severe acute respiratory syndrome (SARS): lessons learnt in Hong Kong

1 reference

12 December 2020

Post-exposure passive immunisation for preventing measles

1 reference

12 December 2020

The prevention of chickenpox in high risk children. Comparison of the effectiveness of specific immunoglobulins and of defibrinated convalescent plasma. 414 cases (author's transl)

1 reference

12 December 2020

Neutralizing antibodies and Sin Nombre virus RNA after recovery from hantavirus cardiopulmonary syndrome

1 reference

12 December 2020

Treatment of severe acute respiratory syndrome with convalescent plasma

1 reference

12 December 2020

Convalescent serum and pooled plasma in communicable diseases

1 reference

12 December 2020

[Passive immunotherapy in AIDS: transfusion of plasma rich in anti-p25 antibody (phase I trial)]

1 reference

12 December 2020

Passive immunization protects cynomolgus macaques against Puumala hantavirus challenge.

1 reference

12 December 2020